プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Nick B.に依頼

United States

Protein science PhD, CEO of skin tissue engineering startup, ex-venture capital / business development and strategy

プロフィール概要

CEO of an autologous skin cell therapeutics company for rare disease and wound healing. Extensive experience in protein therapeutics development, conjugation, purification, cell culture, tissue engineering, protein dynamics simulations and experiments (hydrogen-deuterium exchange)

専門分野

• ☆ Computational Biology
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Structural Biology
• ☆ Binding Assays
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ Plasmid DNA
• ☆ Monoclonal Antibody Production
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Biophysics
• ☆ Biotechnology & Bioengineering
• ☆ Recombinant Protein Expression
• ☆ Biomedical Engineering
• ☆ Biomechanics
• ☆ Biological Engineering
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ 3D Cell Culture
• ☆ Synthetic Biology
• ☆ Chemical Biology
• ☆ Biomolecular Engineering
• ☆ Genetic Engineering
• ☆ Protein/Enzyme Engineering
• ☆ Gene Delivery
• ☆ Tissue Engineering
• ☆ Product Evaluation
• ☆ Concept Development
• ☆ Hypothesis
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Literature Search
• ☆ Gap Analysis
• ☆ Presentation Design
• ☆ Technical & Scientific Writing
• ☆ Manuscript & Journal Article Writing
• ☆ Science Communication
• ☆ Scientific Proofreading & Editing
• ☆ Proofreading & Editing
• ☆ Grant Writing
• ☆ Business Strategy
• ☆ Entrepreneurship
• ☆ Business Intelligence
• ☆ Innovation Management
• ☆ Project Management

サービス

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Technical Writing, General Proofreading & Editing

Research Market Research, User Research, Technology Scouting, Fact Checking, Gap Analysis, Scientific and Technical Research, Systematic Literature Review

Consulting Business Strategy Consulting, Scientific and Technical Consulting

Data & AI Data Processing, Data Insights

Product Development Formulation, Product Validation, Concept Development

職務経験

CEO/Founder

AddGraft Therapeutics

11月 2025 - 現在

Research Strategy Consultant

Arcadia Science

11月 2025 - 12月 2025

Innovation Fellow

Scion Life Sciences

12月 2024 - 9月 2025

Graduate Student Researcher

University of Chicago

8月 2019 - 7月 2025

Senior Analyst

Kendall Capital Partners

8月 2024 - 11月 2024

BIo Fellow

Insight Partners

1月 2024 - 6月 2024

Senior Research Associate

Rubius Therapeutics Inc

6月 2017 - 8月 2019

Research Associate

Immunogen Inc

6月 2015 - 5月 2017

Coop Researcher

Genentech Inc

6月 2014 - 5月 2015

学歴

Graduate Student (Biophysical Sciences Graduate Program)

University of Chicago

8月 2019 - 現在

PhD, Biophysical Sciences

University of Chicago

8月 2019 - 7月 2025

Masters of Science (Biomedical Engineering)

Tufts University

5月 2013 - 5月 2014

Bachelors of Science (Biomedical Engineering)

Tufts University

9月 2009 - 5月 2013

認定資格

• 認定資格の詳細は未入力です。

出版物

PREPRINT

Jordan M Mancl, Wenguang G Liang, Nicholas L Bayhi, Hui Wei, William Budell, Joshua H Mendez, Tobin R Sosnick, Bridget Carragher, Clinton S Potter, Wei-Jen Tang (2025). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

Jordan M Mancl, Wenguang G Liang, Nicholas L Bayhi, Hui Wei, William Budell, Joshua H Mendez, Tobin R Sosnick, Bridget Carragher, Clinton S Potter, Wei-Jen Tang (2025). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

Jordan M. Mancl, Wenguang G. Liang, Nicholas L. Bayhi, Hui Wei, William Budell, Joshua H. Mendez, Tobin R. Sosnick, Bridget Carragher, Clinton S. Potter, Wei-Jen Tang (2024). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

JOURNAL ARTICLE

(2021). Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15 . Cancer immunology, immunotherapy : CII.

(2021). Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic . Nature communications.